Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q1 FY2019 Earnings Presentation
9 slides from Angiodynamics's earnings presentation, Sep 27, 2018
Slide 1: AngioDynamics First Quarter 2019 Earnings Presentation
AngioDynamics First Quarter 2019 Earnings PresentationSeptember 27, 2018
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: First Quarter 2019 Highlights
First Quarter 2019 Highlights Financial Performance Revenue of $85.3 million, compared to $85.4 million a year agoGross Margin of 52.1%, up 380 bps year over year Adjusted EPS of $0.16, compared to $0.13 a year agoAdjusted EBITDAS of $12.6 million, compared to $11.3 million a year agoCash used in op
Slide 4: First Quarter 2019 Results
First Quarter 2019 Results $ in thousands (except per share data) FY2019 Q1 Results FY2018Q1 Results Change Revenue- Vascular Interventions and Therapies- Vascular Access- Oncology - United States- International $85,34049,99523,79011,55567,68417,656 $85,41149,86523,23812,30868,93116,480 (0.1)%0.3%2.
Slide 5: Revised FY2019 Guidance
Revised FY2019 Guidance RevenueAdjusted EPS Free Cash Flow* Previous Guidance$344 - $349m$0.82 - $0.86$38m - $43m Revised Guidance$354 - $359m$0.82 - $0.86$26m - $31m* * Revised guidance includes the cash payment related to the DOJ legal matters previously disclosed, which was paid in 1Q FY2019.
Slide 6: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation
Slide 7: Reconciliation of GAAP to Non-GAAP Gross Profit, Net Income, and EPS
Reconciliation of GAAP to Non-GAAP Gross Profit, Net Income, and EPS Amounts in thousands
Slide 8: Reconciliation of Net Income to EBITDAS to Adjusted EBITDAS
Reconciliation of Net Income to EBITDAS to Adjusted EBITDAS Amounts in thousands
Slide 9: Growth through Focus, Execution, Accountability
Growth through Focus Execution Accountablity ® angiodynamics